PharmaTelevision - Part 2: Is the Emerging Asian Market an opportunity for biotech or pharma?

PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: Part 2: Is the Emerging Asian Market an opportunity for biotech or pharma?

Visitors: You are watching a 5 minute preview.

Get more information and subscribe now

RSS

Twitter

In This Episode:

Summary
Transcript
Participants
Company

In this panel discussion Fintan Walton looks at the emerging Asian markets and asks his guests what opportunities they see for different sectors of the industry in this arena. Sandy Macrae, Senior Vice President for GSK's Asia Pacific Japan and Emerging Markets R&D, Ken Macleod, Partner at Paul Capital Healthcare and Bill Guo, Chairman of Venturepharm give their views on this topic following their diverse experiences of the rising Asian biopharma industry.

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

Innovation, Funding and expanision in emerging markets.

Fintan Walton:

So when we go to UK and you are looking at the innovations component part one of the things, one of the features that we've seen as you've already mentioned in countries like India is particularly which has already got a mature pharmaceutical industry and also manufacturing industry that innovation is not necessarily coming through biotech companies per say but through these more mature companies?

Ken Macleod:

I think what you see there is that one of the things that people I do think are focused on is the fact that in manufacturing there is a price advantage and that's undoubtly true, but I think in the same way on the R&D side in say in China there are also some real innovative advantages, innovation advantages in India and these countries as well on the manufacturing side, that the formulation work that is done in India is now as good as it is anywhere else in the world. And you then start to see that be done with some cost advantages as well, so you see some real innovation there. So I think that's not just on the new chemical entity our development work it's on the existing products as well generic products as well. And then if you then go back to the sort of the new work that's been done the new drugs that been developed yeah those are by enlarge being primarily developed within those companies, now there are one or two start ups which have received some funding there are some venture funds from the US and Europe that have invested in companies in India and there are one or two Indian venture firms that have funded start ups as well, but I would still say that primarily that the funding which is the serious funding that's required it's being funded from the revenue streams there have been generated through selling branded generics in the home market or generics in the international markets, so

Fintan Walton:

But for the local companies within the emerging markets and let's say use India as an example again their need to grow is obviously growing within their own country but they also need to grow outside their own country

Ken Macleod:

Absolutely.

Fintan Walton:

In order to get that dominance?

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

Bill Guo

Chairman and founder of Venturepharm Group

Dr Sandy Macrae is Senior Vice President for GSK's Asia Pacific Japan and Emerging Markets R&D, a team that seeks and develops medicines for those markets. He trained in medicine and pharmacology at Glasgow University and then specialized in endocrinology at the Royal Postgraduate Medical School, Hammersmith Hospital, London. He has a PhD in genomics from King's College Cambridge and completed his post doctoral research work at Duke University, USA. Sandy first joined SmithKline Beecham(now GlaxoSmithKline) in Neurosciences in 1997. Since then he has held a number of positions including Vice President for Scientific Licensing in Worldwide Business Development, Vice President in Clinical Development for Musculoskeletal, Inflammation, Gastroenterology and Inflammation, and Vice President for Infectious Diseases which included leading their Diseases of the Developing World clinical group. Ken Macleod, Ph.D. joined Paul Capital Partners in 2004 and is responsible for sourcing, evaluating and negotiating European and Asian investment opportunities for Paul Capital Healthcare. Based in London, Dr. Macleod previously held senior management positions over a 15-year career at Serono, Abbott Laboratories, and Beecham Pharmaceuticals. Prior to joining Paul Capital Partners, Dr. Macleod was a Venture Partner at Schroder Ventures Life Sciences where he was responsible for deal sourcing, evaluation, and negotiation of pharmaceutical investment opportunities. Dr. Macleod earned his Ph.D. from the University of York, UK and his B.Sc. with honors in Biology from the University of Manchester, UK. Bill Guo is the Chairman and founder of Venturepharm Group, a leading full service provider to world life science industry. Venturepharm Group now has two public companies, Venturepharm Lab, the first China CRO listed in Hong Kong and CBI, the first Chinese CRO's acquisition of a US CRO in NASDAQ. Having obtained the medical degree in China, Bill went to Canada to pursue his MSc and PhD studies in pharmacokinetics and physical \pharmaceuticals at the University of Toronto, and obtained MBA from Herriot Watt University and Executive Education from Judge Business School, University of CambridgeUK. Fortune magazine recognized him as one of the most promising entrepreneurs in China. A list of his awards includes 2005 National Hero by the State Council of China; One of the Ten Best Management Elites in China (2004); one of the ten most influential individuals in economic field of China (2005); Sole winner of Youth Chinese Entrepreneur Award by Asia Business Week (2003); 2005 Entrepreneurs and Innovation by British Chamber of Commerce.

GlaxoSmithKline

GlaxoSmithKline Plc is a United Kingdom based pharmaceutical, biological, and healthcare company. It is the world's second largest pharmaceutical company and a research-based company with a wide portfolio of pharmaceutical products covering anti-infectives, central nervous system, respiratory, gastro-intestinal/metabolic, oncology, and vaccines products. It also has a Consumer Healthcare operation comprising leading oral healthcare products, nutritional drinks, and over the counter medicines. GSK was formed in 2001 by the merger of GlaxoWellcome (formed from the mergers of Burroughs Wellcome & Company and Glaxo Laboratories), and SmithKline Beecham (from Beecham, and SmithKline Beckman). Paul Capital PartnersPaul Capital Partners established Paul Capital Healthcare in 1999 to meet the financing needs of healthcare companies, institutions and inventors. Today, the firm manages one of the largest dedicated healthcare funds globally with a total of $1.4 billion in assets under management. The Fund focuses on commercial stage healthcare products and investment opportunities in North America, Europe, and Asia. To date Paul Capital Healthcare has closed more than 30 investments in the pharmaceutical, biotechnology, medical device, and diagnostics areas. Public and private companies, research institutions and universities, and individual inventors have all benefited from the flexibility of Paul Capital Healthcare's investment approach. This capital has enabled them to transfer product risk, finance clinical and commercial development projects, acquire new products, fund university programs and capital needs, avoid conflicts of interest, unlock shareholder value, and monetize product royalties. Venturepharm GroupVenturepharm Asia is a global life science leader with a strategic focus on venture capital, merchant banking, CRO, CMO, CSO, compound partnering, and royalty sharing. The group develops an innovative full service plus model to position itself strongly in the life science industry. Currently Venturepharm Asia has more than two thousand employees. Venturepharm is the largest global provider of pharmaceutical development service in China. Venturepharm provides full service of drug discovery and development that take new drugs from "Idea to patients". These include API (Active Pharmaceutical Ingredient), formulation development, clinical trial, product registration, marketing & sales to pharmaceutical distributors and patients in China and overseas. Listed as a Hong Kong public company (8225), Venturepharm (China) has experienced dramatic success since its inception in 1999. Powered with 7 of Smart technology platforms, it has over 400 non-patent infringed products approved, or pending. In addition, 6 of NCEs (new chemical entities) are at preclinical stage. These products encompass over 13 major therapeutic areas. In 2004, Venturepharm was valued by FORTUNE magazine as one of the five most promising companies in China. Since 2000, Venturepharm has achieved revenue CAGR of 133% and EPS CAGR of 383% annually.